98%
921
2 minutes
20
Purpose: Hepatic hydrothorax is a complication of decompensated liver cirrhosis that is difficult and complex to manage. Data concerning the optimal treatment method, other than liver transplantation, are limited. This study aimed to compare the clinical features and outcomes of patients treated with various modalities, while focusing on surgical management and pigtail drainage.
Materials And Methods: Forty-one patients diagnosed with refractory hepatic hydrothorax between January 2013 and December 2017 were enrolled.
Results: The mean Child-Turcotte-Pugh and model for end stage liver disease scores of the enrolled patients were 10.1 and 19.7, respectively. The patients underwent four modalities: serial thoracentesis (n=11, 26.8%), pigtail drainage (n=16, 39.0%), surgery (n=10, 24.4%), and liver transplantation (n=4, 9.8%); 12-month mortality rate/median survival duration was 18.2%/868 days, 87.5%/79 days, 70%/179 days, and 0%/601.5 days, respectively. Regarding the management of refractory hepatic hydrothorax, surgery group required less frequent needle puncture (23.5 times in pigtail group vs. 9.3 times in surgery group), had a lower occurrence of hepatorenal syndrome (50% vs. 30%), and had a non-inferior cumulative overall survival (402.1 days vs. 221.7 days) compared to pigtail group. On multivariate analysis for poor survival, body mass index <19 kg/m², refractory hepatic hydrothorax not managed with liver transplantation, Child-Turcotte-Pugh score >10, and history of severe encephalopathy (grade >2) were associated with poor survival.
Conclusion: Serial thoracentesis may be recommended for management of hepatic hydrothorax and surgical management can be a useful option in patients with refractory hepatic hydrothorax, alternative to pigtail drainage.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6753336 | PMC |
http://dx.doi.org/10.3349/ymj.2019.60.10.944 | DOI Listing |
ACG Case Rep J
September 2025
Department of Medicine, University of Arizona College of Medicine, Tucson, AZ.
Hepatic hydrothorax (HH) occurs in 4%-12% of patients with cirrhosis and rarely presents without accompanying evidence of clinically significant portal hypertension (CSPH). We report the case of a 65-year-old man with cirrhosis without prior decompensation, congestive heart failure, and recurrent right-sided pleural effusion. CSPH was not otherwise observed despite thorough laboratory, radiologic, and endoscopic evaluation.
View Article and Find Full Text PDFPurpose Of The Review: To review epidemiology, pathogenesis, diagnosis, and management of hepatic hydrothorax.
Recent Findings: Refractory hepatic hydrothorax is an independent predictor of mortality in patients with decompensated cirrhosis. Allocation of Model for End-Stage Liver Disease exception points for patients with refractory hydrothorax was found to be associated with a significant reduction in post liver transplant mortality.
Tech Vasc Interv Radiol
September 2025
Division of Interventional Radiology, Department of Radiology, University of Texas Southwestern Medical Center, Dallas, TX. Electronic address:
Transjugular intrahepatic portosystemic shunt (TIPS) is a key therapeutic intervention in the management of portal hypertension and its complications, such as variceal bleeding, hepatic hydrothorax, and refractory ascites. TIPS has historically been used as a lifesaving measure or as a bridge to liver transplantation (LT). Despite its efficacy, creation of a TIPS can be associated with significant morbidity, particularly in patients with decompensated cirrhosis.
View Article and Find Full Text PDFTherap Adv Gastroenterol
July 2025
Department of Hospital Medicine, Mayo Clinic Health System, Eau Claire, WI, USA.
Hepatic hydrothorax (HH) is a rare but serious complication of end-stage liver disease that is often refractory to conventional medical and procedural management. This case report describes a 75-year-old woman with HH secondary to cirrhosis from metabolic-associated steatotic liver disease. Her clinical course was marked by recurrent hospitalizations, refractory right-sided pleural effusion, and multiple unsuccessful interventions including diuretics, serial thoracenteses, an indwelling pleural catheter, and chemical pleurodesis.
View Article and Find Full Text PDFCureus
July 2025
General Surgery, International Medical Center, Jeddah, SAU.
Porous diaphragm syndrome (PDS) is a rare and underrecognized condition characterized by the transdiaphragmatic migration of peritoneal contents into the pleural cavity through defects in the diaphragm, most often affecting the right hemidiaphragm. It is commonly associated with hepatic hydrothorax, peritoneal dialysis-related hydrothorax, and peritoneal carcinomatosis. Despite its anatomical simplicity and the availability of effective surgical treatment, PDS is frequently misdiagnosed, leading to repeated pleural drainage, inappropriate therapies, and treatment delays.
View Article and Find Full Text PDF